Medical Newswire

Medical Newswire!

Medicine, Healthcare, Medical Research, Hospitals, Management
Press release distribution service
Home | Medical-Newswire.Com:

VFC's Stock House: NovaBay (NBY) May Be Highly Undervalued

(EMAILWIRE.COM, March 21, 2012 ) New York, NY -- NovaBay Pharmaceuticals (NBY) released news this week that offers to broaden the scope and reach of the company's Aganocide compounds, which are being positioned as anti-infectives and could potentially replace modern day antibiotics as resistance to such treatment grows.

On Tuesday NovaBay announced a deal with Virbac Animal Health to bring its technology to the veterinary market. According to the agreement, NovaBay will receive an upfront payment - and some additional support for research and development - while Virbac will retain the option to license any of the Aganocide compounds that are successfully applied to treating veterinary indications.

The deal could provide NovaBay with a steady revenue stream in the future if Virbac exercises its licensing option. According to the Tuesday press release, if the option is exercised,

"NovaBay may receive additional payments, which include an exercise fee as well as development and pre-commercial milestones for a line of veterinary products. NovaBay will also receive royalties on sales of any successfully commercialized Aganocide products to arise from this agreement."

Few companies are going to become superpowers in the field of medicine on treating veterinary indications alone, but the deal brings some attention back to NovaBay and gives us another chance to consider this company's technology on the open market - should the pipeline products make it that far.

It also gives us the opportunity to determine whether or not the current market capitalization for NBY justifies that pipeline potential, which, in the opinion of this writer, the determination is "probably not."

First, let's revisit the problem of antibiotic resistance.

When introduced into society seventy years ago, antibiotics changed the shape of medicine, and provided what - at the time - was considered a huge leap forward in treating bacterial infections. Having been so widely-used since then, however, the infectious organisms against which the antibiotics are administered have grown increasingly resistant, and sometimes immune, to today's antibiotic treatments.

The Centers for Disease Control and Prevention considers the developing resistance to antibiotics as a "crisis", noting on its website that, "These drugs have been used so widely and for so long that the infectious organisms the antibiotics are designed to kill have adapted to them, making the drugs less effective. People infected with antimicrobial-resistant organisms are more likely to have longer, more expensive hospital stays, and may be more likely to die as a result of the infection."

Medical professionals themselves understand the growing risks associated with antibiotic resistance, as noted by Dr. Marc Siegel, associate professor of medicine and medical director of Doctor Radio at NYU Langone Medical Center, this week in an article published on FoxNews.com. Dr. Siegel also notes that Doctors continue to over prescribe these treatments, thereby strengthening the resistance of the surviving bacteria and creating new "super colonies" that will eventually be uncontrollable.

This dilemma has created a huge monetary burden on the global health care system and is possibly setting up a one-time "miracle cure" as irrelevant.

That's where NovaBay comes into the picture.

NovaBay has developed, through its proprietary Aganocide compounds, a pipeline of synthetic anti-infectives that are designed to mimic the body's own defenses against infection. Namely, these synthetic molecules, based on the Aganocide compound NVC-422, essentially act in the same manner and processes of a body's white blood cells and not as antibiotics, therefore significantly reducing the risk of a resistance being developed.

The potential of such a technology has market-moving implications, and under the circumstances, it's understandable why NBY could be tagged with an 'undervalued' label.

There are, however, a couple of reasons why investors may not yet have fully embraced the company and its technology. The first reason may be the most obvious one; that NovaBay still has nothing beyond Phase II, and therefore any investment in the company is highly speculative and risky at this point, which is a fair assessment.

That said, the best deals in biotech are the ones that are found early, when patience is needed as the trial results pan out. It's also worth noting, however, that he trend of staying away from speculative "Phase II" investments may be shifting.

Take Lpath, Inc. (LPTN), for example. Lpath also has a novel and potentially groundbreaking technology in the works, but Pfizer (PFI) has bucked the Phase II label of the company and jumped in with a very significant partnership.

CellDex Therapeutics (CLDX) is another one that has traded very highly during its Phase II stages, even when Pfizer decided to divorce itself from a partnership with the company.

In both cases, investors may have started to become clued in to how much market potential is contained within those respective pipelines and tossed the standard "wait until Phase III" strategy to the side. As investors with similar strategies in mind research NovaBay, the same potential for price appreciation exists; especially give the fact that NBY has a powerhouse partner of its own in Galderma SA, with whom NovaBay is developing a treatment for the highly-contagious skin condition, Impetigo.

Another reason why NovaBay may be missing the mark in terms of market cap right now, and this one may be more relevant than the last, is that an earlier clinical trial conducted with then-partner Alcon in the treatment of adenoviral conjunctivits - better known to the average Joe as "pink eye" - failed.

Shares slumped badly after that news hit the presses and have only barely recovered since.

On the flip side to the endpoint miss, however, which sent sent investors running for the doors, is that a further look at the data from the same trial did show that efficacy was demonstrated against Epidemic Keratoconjunctivitis (EKC), possibly the most contagious form of the infection, and which often threatens a victim's vision.

Based on that data, trials have continued, but the fact that the company has a failed trial under its belt most certainly deters some investors from jumping back in, at least until they see more results.

A Phase IIb trial for this indication is expected to begin within months, while another Phase II trial for the Impetigo condition is also slated for this year.

Results from 'Part A' from a trial testing NVC-422 as a treatment for urinary catheter blockage and encrustation (UCBE) have already rolled in, with results from 'Part B' also due within months.

The pending trial results provide some short term catalysts, but another catalyst due for this year could be the one that puts NovaBay on the map.

A commercial launch is planned for the short to mid term for NeutroPhase, NBY's first FDA-cleared product and a treatment for chronic wound in both hospital and personal care. A successful launch for NeutroPhase could alleviate many of the monetary concerns normally associated with a small company bringing its pipeline through trials, and just a couple of months ago the company announced its first strategic partner for NeutroPhase.

Having a product already on the market and bringing in revenue will go a long way to validating this small company in the eyes of potential investors, especially if the NeutroPhase commercial launch goes off without a hitch.

Based on the pending trial catalysts, the commercial launch of NeutroPhase, and most importantly, the potential of NVC-422 products on the open market as eventual substitutes for antibiotics, NBY may still be trading under the radar and could still be lightly valued, when all is considered.

By 2013 the NovaBay could have three Phase III trials ongoing with an FDA approved product on the market.

If that's the case, it's a fair bet to assume that the market cap will be significantly higher than thirty five million at that point.

For an example of how a shift from Phase II to Phase III can effect a market cap, one could look at Keryx BioPharmaceuticals (KERX). During the early to mid stages of Phase II, the KERX market cap was similar to NBY's now, but when Phase II trials were successful and Phase III came along?

Prices quickly quadrupled.

NovaBay's target market of anti-infective care is a multi-multi-billion dollar market annually, and NBY could quickly penetrate that market, as Doctors are currently looking for a way around antibiotic resistance.

As I've previously discussed, this company may be at the right place at the right time. For investors being in the right place at the right time means being "in" before any price run starts, and it's possible that NBY has a ways to move, should the pending catalysts turn out positive.

Disclosure: Long NBY.

For more information and commentary regading NBY, visit: http://vfcsstockhouse.com/blog/article/-novabay-may-be-in-the-right-place-at-the-right-time-with-an-answer-for-antibiotic-resistance

or

http://vfcsstockhouse.com/blog/article/-nby-key-deal-marks-a-year-of-swift-progression

Contact VFC's Stock House: vfc@vfcsstockhouse.com

About VFCsStockHouse.com:

VFC's Stock House offers research-based investment information, insights and ideas on a variety of different companies in numerous sectors, with a focus on biotech stocks and healthcare.

For full reports on Celsius Holdings and other companies visit: http://vfcsstockhouse.com

Follow VFC's Stock House on Twitter: https://twitter.com/#!/VFCsStockHouse

'Like' VFC's Stock House on Facebook: http://www.facebook.com/pages/VFCs-Stock-House/143724412345213

For full disclaimer visit: http://vfcsstockhouse.com


VFC's Stock House
VFC
240-786-2111
vfc@vfcsstockhouse.com

Source: EmailWire.com


Medical Resources
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Healthcare resource center today to browse our selection of 600+ complimentary Healthcare magazines, white papers, webinars, podcasts, and more. Get popular titles including:

Eyecare Business
Medical Laboratory Observer
FierceHealthcare

No credit cards, coupons, or promo codes required. Try it today!

Medical Sponsors

Health News
Health News Headlines - Yahoo News
Health News Headlines - Yahoo News
Get the latest health news headlines from Yahoo News. Find breaking health news, including analysis and opinion on top health stories.

Beijing snuffs out suburban BBQs in pre-Olympic smog fight
6 May 2015 at 7:24pm
Beijing has extended a ban on outdoor barbecues to restaurants operating in some suburban areas as it tries to improve its notoriously poor air quality in case it wins the 2022 Winter Olympics, state news agency Xinhua reported. The government blames them for contributing to smog, despite much public ridicule that dirty factories are more to blame. The outlying suburb of Tongzhou, as well as parts of Shunyi, Miyun, Pinggu and Fangshan, will now have to follow the ban, the report issued late on Wednesday said, citing the Beijing Municipal Bureau of City Administration and Law Enforcement. Xinhua said this was part of efforts to ensure air quality is up to scratch in case Beijing wins the 2022 Games, a decision that will be made in late July.

Olympics-Beijing snuffs out suburban BBQs in pre-Olympic smog fight
6 May 2015 at 7:09pm
Beijing has extended a ban on outdoor barbecues to restaurants operating in some suburban areas as it tries to improve its notoriously poor air quality in case it wins the 2022 Winter Olympics, state news agency Xinhua reported. The government blames them for contributing to smog, despite much public ridicule that dirty factories are more to blame. The outlying suburb of Tongzhou, as well as parts of Shunyi, Miyun, Pinggu and Fangshan, will now have to follow the ban, the report issued late on Wednesday said, citing the Beijing Municipal Bureau of City Administration and Law Enforcement. Xinhua said this was part of efforts to ensure air quality is up to scratch in case Beijing wins the 2022 Games, a decision that will be made in late July.


Obese kids face stigma, flunk school: European research
6 May 2015 at 6:57pm

Obese children are far less likely to finish school than peers of normal weight, according to European research Thursday which also highlighted body image problems in kids as young as six. Britain had the second-highest rate with 23.1 percent, followed by Albania with 22 percent and Georgia with 20 percent, Bulgaria with 19.8 percent and Spain with 18.4 percent, said an analysis of data provided by 32 countries in the World Health Organization's 53-member Europe region. People are classified overweight if they have a BMI (body weight index, a ratio of weight to height) of 25 and higher, and obese from a BMI of 30. A second study presented at the congress said only 56 percent of children in Sweden who had received treatment for obesity completed 12 years or more of school, compared to 76 percent of normal-weight peers.



Under pressure, FDA to hold public meeting on off-label use
6 May 2015 at 6:35pm

By Toni Clarke WASHINGTON (Reuters) - The U.S. Food and Drug Administration will hold a public meeting this summer to address drug company concern that restrictions on what they can say about off-label use of drugs violate their First Amendment right to free speech. The meeting, announced last month by FDA chief counsel Elizabeth Dickinson, comes as a bill known as 21st Century Cures, designed to speed new drugs to market, is moving through Congress. Efforts by drug companies to change the rules gained steam after a 2012 decision from the Second Circuit Court of Appeals, which overturned the conviction of Alfred Caronia, a sales representative for Orphan Medical, which was later acquired by Jazz Pharmaceuticals Inc. After Caronia was caught talking to physicians about various off-label uses of the narcolepsy drug Xyrem, the court said the First Amendment protected truthful and non-misleading off-label speech.


Cuba says to send 48-member medical team to Nepal
6 May 2015 at 6:15pm
The Cuban government will send a 48-member medical team including 22 doctors to Nepal in response to the April 25 earthquake that killed more than 7,600 people, official Cuban media said on Wednesday, citing Health Ministry officials. The Communist government has traditionally sent medical teams abroad in response to disasters, including last year when Cuba sent 256 doctors and nurses to three West African countries to treat patients in the Ebola outbreak. While Cuba provides doctors and nurses for disaster relief for free, it also exchanges them for cash or goods on more routine missions.


Thailand's new weapon to beat deep-south insurgency: DNA swabs
6 May 2015 at 4:58pm

By Amy Sawitta Lefevre YALA, Thailand (Reuters) - Thailand's military government has introduced a new strategy to curb the insurgency that has rumbled on in the country's jungle-blanketed deep south for more than a decade: DNA swabbing. It has been widely panned for mishandling the economy and undermining democracy, but the top brass that seized power a year ago can point to a drop of more than 50 percent in attacks by Muslim Malay rebels across the restive region. The Muslim Attorney Centre in the province of Pattani says security-related charges this year are set to exceed 2014's, in part because more DNA evidence is being used. While the military credits DNA collecting for the decrease in violence, lawyers and activists say the forced sweeps are further alienating locals in the Muslim-dominated provinces of Pattani, Yala and Narathiwat that were annexed by Thailand a century ago.


Despite U.S. efforts, bird flu thought to spread between farms
6 May 2015 at 4:55pm
By Tom Polansek CHICAGO (Reuters) - Poultry veterinarians in Minnesota believe an outbreak of avian flu has spread between farms, indicating the implementation of a U.S. strategy to contain the deadly bird disease failed in at least some cases. Wild birds are thought to be carriers of the flu virus, which can be tracked onto poultry farms by people or trucks that come into contact with contaminated feces. The U.S. Department of Agriculture, which until now has focused on water fowl spreading the bird flu, is investigating "the potential transmission of virus between operations," a spokeswoman said. In Minnesota, the biggest U.S. turkey producing state, delays in the killing of infected poultry flocks may have led to "a couple of cases" of the flu spreading from one farm to another, said Steve Olson, executive director of the Minnesota Turkey Growers Association.

Uganda's women, girls seek justice to halt sexual violence: rights group
6 May 2015 at 4:07pm
By Kieran Guilbert LONDON (Thomson Reuters Foundation) - Tackling an "epidemic" of sexual violence in Uganda, in which disabled women and girls are most vulnerable to abuse, and seeking justice for the victims are at the heart of a campaign launched by the rights group Equality Now on Thursday. The #JusticeForGirls initiative will enable women and girls who suffer sexual violence to pursue justice through local channels, avoiding the slow, complex and expensive process of taking a case to court, Equality Now said. Victims have a "bleak prospect of accessing justice for such atrocious crimes", said the group's legal consultant, Kimberly Brown. Uganda is in the midst of a sexual violence epidemic, and most perpetrators go unpunished, the rights group said.


Who Should Teach Mindfulness Meditation?
6 May 2015 at 3:49pm

More and more people want to learn how to practice mindfulness meditation. This is wonderful, really, because the practice brings many benefits directly to individuals and, through them, to society at large. And, as demand increases so too does supply. As a result, there are more and more opportunities for learning mindfulness, both in secular...



IBM's Watson to guide cancer therapies at 14 centers
6 May 2015 at 3:27pm

(This version of the story has been refiled to correct name of USC unit participating in program, in the 12th paragraph) By Sharon Begley NEW YORK (Reuters) - Fourteen U.S. and Canadian cancer institutes will use International Business Machines Corp's Watson computer system to choose therapies based on a tumor's genetic fingerprints, the company said on Tuesday, the latest step toward bringing personalized cancer treatments to more patients. Oncology is the first specialty where matching therapy to DNA has improved outcomes for some patients, inspiring the "precision medicine initiative" President Barack Obama announced in January. Watson can do it in minutes and has in its database the findings of scientific papers and clinical trials on particular cancers and potential therapies. Faced with such a data deluge, "the solution is going to be Watson or something like it," said oncologist Norman Sharpless of the University of North Carolina Lineberger Cancer Center.


Life Alert accused of sexual harassment in ex-worker's lawsuit
6 May 2015 at 3:22pm
By Jonathan Stempel NEW YORK (Reuters) - The maker of Life Alert, known for its television ad slogan "Help, I've fallen and I can't get up," has been sued by a former sales manager who claims he was fired because of his age and cancer diagnosis, and his complaints about "rampant" sexual harassment in the company's Manhattan office. In a $7 million lawsuit filed on Wednesday in the New York state court in Manhattan, Leon Hayblum claimed that Life Alert Emergency Response Inc illegally terminated him without warning last Nov. 10, when he was 71, after a dozen years on the job. Hayblum said this was done in retaliation for his "years" of complaints about the alleged harassment and Life Alert's alleged misclassification of sales staff as independent contractors, and because he had been diagnosed with prostate cancer. Life Alert is based in Encino, California, and sells wearable devices intended to help elderly or disabled people call for assistance when they face medical or other emergencies.


EPA suggests triggers for warning of algae in drinking water
6 May 2015 at 3:20pm

TRAVERSE CITY, Mich. (AP) ? The U.S. Environmental Protection Agency released the first nationwide guidelines Wednesday for determining when algal toxins have reached dangerous levels in public water systems and do-not-drink warnings might be needed.



Colorado cinema gunman's professors recall quiet, awkward student
6 May 2015 at 3:10pm

By Keith Coffman CENTENNIAL, Colo. (Reuters) - Lawyers in Colorado's movie massacre trial painted dueling portraits of gunman James Holmes' sanity on Wednesday as they quizzed his former neuroscience professors on his work, attitude and behavior in class. Just weeks before the rampage, Holmes dropped out of a doctoral program at the graduate school of the University of Colorado's Anschutz Medical Campus in Aurora, the Denver suburb where the onslaught took place. Two professors who supervised him at the medical school told jurors he was a quiet student who excelled in written work but appeared to lack effort in the lab, was socially awkward, and sometimes used jokes in presentations that fell flat with classmates. Assistant Professor Achim Klug, who oversaw Holmes' first assigned stint in a laboratory, said the defendant would only speak when called on, but that he usually got the answer right.



US must lead on AIDS funding: Elton John
6 May 2015 at 2:59pm

Elton John forecast Wednesday the end of AIDS in his lifetime -- but only if the United States keeps leading the world in bankrolling its eradication. The British pop music icon and AIDS activist was the star turn at a Senate hearing on future funding for the United States' core global AIDS initiative. "The AIDS epidemic is not over and America's continued leadership is critical," the 68-year-old John warned. "We cannot afford to let the window close if our efforts flag," added the founder of the Elton John AIDS Foundation, which has raised more than $321 million since 1992 for AIDS treatment and prevention.


Skinny Mom's 6-Pack Abs Are Back Just Weeks After Giving Birth
6 May 2015 at 2:52pm
Model Sarah Stage, who stunned on Instagram with a tiny pregnant belly, is back. And she's brought a bikini.

Pharmanewswire.com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright GroupWeb Media LLC. All Rights Reserved.

For unlimited press release distribution for $99 per month, call (281) 645-4086 or start posting your press releases online at EmailWire.com. CityRegions.Com is part of GropWeb Network, online properties of GroupWeb Media LLC. Copyright 2012 GroupWeb Media LLC. All Rights Reserved.


GroupWeb Media Network
AfricaNewswire.Net | AppleNews247.Com | AsiaNewsWire.Net | Aviation-NewsWire | Energy Industry | EstateNewsWire | Entertainment-NewsWire.com | Food Beverage News | Glamour NewsWire | Health NewsWire | Hosting NewsWire | i-Auto NewsWire | i-Business News | EuropeNewsWire.Net | iCameroon.com | i-Canada-News.Com | i-SoftwareNews.com | iT-NewsWire.Com
| InvestorsNewsDesk.Com | i-TravelNewsWire.Com | LegalLaw247.com | Medical-NewsWire.com | MiningNewsWire.net | MoneyNewsWire.Net | Movie-Stars-News.Com | PayDayNews247.Com | PharmaNewsWire.Com | Publishing-NewsWire.Com | Shopping-NewsWire.com | Telecom-NewsWire.Net | Transportation-News.Com | USGovernment-News.Com | WebPosters.Net | Wireless-NewsWire.Com |
Medical-Newswire.com - Medicl Newswire and Press Release service of GroupWeb Media LLC